The effects of U-ISGF3 on DNA damage resistance and the fact that IRF9 overexpression leads to resistance against several chemotherapeutics indicates that IRF9 could affect tumor therapy, which in turn helps explain the oncogenic properties of IRF9 [18,39,43]. This evidence concerns the gene STAT1 and neoplasm.